BRD2 and myeloid sarcoma: The most frequent antibody targets in MS patients were p120-CagA (73.3%), p66-UreB (66.7%), p67-FSH (55%), p50 (53.3%), and p26 (51.7%), being recognized by more than half of MS patients.